Agitation thrombolysis combined with catheter-directed thrombolysis for the treatment of non-cirrhotic acute portal vein thrombosis

Table 1 Characteristics of the included patients

Patient No.	Age (yr)	Sex	Etiology	Symptoms	Time from onset to treatment (d)
1	29	M	Myelodysplastic syndromes	Abdominal pain, abdominal distension	4
2	39	F	Protein S deficiency	Abdominal pain, abdominal distension, vomiting	11
3	43	M	Myelodysplastic syndromes	Abdominal pain, vomiting	14
4	48	F	Protein C deficiency	Abdominal pain, abdominal distension	5
5	40	F	Nephrotic syndrome	Abdominal pain, vomiting	8
6	53	M	Protein S deficiency	Abdominal pain, diarrhea	2
7	61	F	Splenectomy after trauma	Abdominal pain, abdominal distension, vomiting	10
8	36	F	Myelodysplastic syndromes	Abdominal pain, abdominal distension	5
9	57	F	Unknown	Abdominal pain	16

F: Female; M: Male.

Table 2 Results of treatment and follow-up

Patient No.	Treatment route	Duration of CDT (d)	Dose of urokinase (× 106 IU)	Complications	Follow-up time (mo) and results
1	TIP	2	1.0	Hematuresis	27/patent
2	PT	2	1.4	None	23/patent
3	TIP	-	-	Death	Death
4	TIP	1	0.8	None	31/patent
5	PT	3	2.0	Hemorrhage from the puncture tract	5/patent
6	TIP	4	2.6	Subcapsular hematoma	22/reappearance
7	TIP	1	0.8	None	9/patent
8	TIP	1	0.8	None	12/patent
9	PT	3	2.0	Hemorrhage from the puncture tract	18/patent

PT: Percutaneous transhepatic; TIP: Transjugular intrahepatic portosystemic.

Table 3 Changes in liver function and portal vein hemodynamics

	Pre-treatment	Post-treatment	P value
Albumin, g/L	34.9 min	36.7 min	0.872
Alanine aminotransferase, U/L	38.2 inea	33.6 inea	0.934
Total bilirubin, sferase	17.9 lbi	17.4 lbi	0.991
Flow velocity of the portal vein, cm/s	4.2 tal	16.3 alv	< 0.05
Maximum lumen occupancy of PVT, %	78.2 occ	14.1 occ	< 0.01
Portal pressure, mmHg	31.0 alp	14.1 alp	< 0.05

PVT: Portal vein thrombosis.